Applera Renamed Applied Biosystems Following Celera Separation.

Applera Corporation has completed the separation of its Celera business and is now renamed Applied Biosystems Inc. Celera Corporation is an independent publicly traded company and holds the businesses, assets, and liabilities previously attributed to the Celera Group.

Applied Biosystems Inc., formerly known as Applera Corporation, has completed the separation of its Celera business and is now an independent publicly traded company. This move comes at a time when the biological safety testing market is experiencing robust growth, driven by increasing demand for biologics, vaccines, and gene therapies, as well as stricter regulatory mandates worldwide [1].

The biological safety testing products and services market was valued at USD 4.62 billion in 2023 and is projected to reach USD 11.58 billion by 2032, growing at a CAGR of 10.77% over the forecast period 2024–2032 [1]. This growth is propelled by the expanding biopharmaceutical industry and the increasing regulatory requirements for product safety. The market is segmented by product, application, and test type, with reagents and kits, vaccines and therapeutics, and endotoxin tests being the key segments [1].

North America, particularly the United States, held the largest share of the market in 2023, driven by its well-established biopharmaceutical sector and stringent safety regulations. The Asia Pacific region, however, is projected to be the fastest-growing, driven by the rapid expansion of the biotechnology sector in countries like China, India, and Japan [1].

Applied Biosystems Inc. is well-positioned to benefit from this growth. The company offers a wide range of biological safety testing products and services, including reagents, kits, and instruments. Its Applied Biosystems qPCR Kits and EndoPrep Endotoxin Testing are widely used in the industry for their reliability and accuracy [1].

Recent developments in the market also highlight the potential for growth. For instance, Lonza launched the Nebula Multimode Reader in 2023, enhancing the efficiency of endotoxin detection in safety testing labs [1]. Similarly, BioMérieux introduced a new pyrogen testing system designed to improve patient safety in biologics testing [1].

In conclusion, the separation of Celera from Applera Corporation and the subsequent renaming to Applied Biosystems Inc. marks a significant milestone for the company. As the biological safety testing market continues to grow, Applied Biosystems Inc. is well-positioned to capitalize on this opportunity and contribute to the development of safe and effective biologics, vaccines, and gene therapies.

References:
[1] https://www.globenewswire.com/news-release/2025/05/23/3087522/0/en/Biological-Safety-Testing-Products-and-Services-Market-to-Reach-USD-11-58-Billion-by-2032-Driven-by-Increasing-Safety-Regulations-and-Innovation.html